Oncology Based In-vivo CRO Market Size, Share & Trends Report

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-1-68038-859-6
Number of Pages: 100
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Oncology-Based In-vivo CRO Market, By Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Blood cancer
  - Syngeneic model
  - Patient Derived Xenograft (PDX)
  - Xenograft
- Solid tumors
  - Syngeneic model
  - Patient Derived Xenograft (PDX)
  - Xenograft
- Others
  - Syngeneic model
  - Patient Derived Xenograft (PDX)
  - Xenograft
Oncology-Based In-vivo CRO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Oncology-Based In-vivo CRO Market, By Indication
    - Blood cancer
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Solid tumors
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Others
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
  - U.S.
    - U.S. Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - Canada
    - Canada Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
- Europe
- Asia Pacific
  - Asia Pacific Oncology-Based In-vivo CRO Market, By Indication
    - Blood cancer
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Solid tumors
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Others
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
  - Japan
    - Japan Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - China
    - China Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - India
    - India Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - Australia
    - Australia Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - South Korea
    - South Korea Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - Thailand
    - Thailand Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
- Latin America
- Middle East & Africa
  - Middle East & Africa Oncology-Based In-vivo CRO Market, By Indication
    - Blood cancer
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Solid tumors
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
    - Others
      - Syngeneic model
      - Patient Derived Xenograft (PDX)
      - Xenograft
  - South Africa
    - South Africa Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - Saudi Arabia
    - Saudi Arabia Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - UAE
    - UAE Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
  - Kuwait
    - Kuwait Oncology-Based In-vivo CRO Market, By Indication
      - Blood cancer
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Solid tumors
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft
      - Others
        
        Syngeneic model
        
        Patient Derived Xenograft (PDX)
        
        Xenograft

Oncology Based In-vivo CRO Market Dynamics

Driver: Economic Efficiency

Outsourcing to researchers benefits sponsors in multiple ways such as productivity, time, and costs. An additional benefit of 90-100 million may be estimated if the product is a market mover and has the fastest time to market. Various strategic and market leaders have calculated and estimated a cost saving of about three to seven million on an average in case of outsourcing to offshore. In terms of offshore outsourcing, the sponsors gain a dual benefit of reduced cost and better profiling of the drug molecule in different races, thereby driving the market for outsourcing.

Driver: Increasing Mergers And Collaborations

Growing number of mergers and collaborations increased pharmaceutical outsourcing along with major key players expanding into developing regions. Providers are collaborating with different companies to increase their capabilities and offer more services. n 2015, LabCorp acquired Covance for USD 5.5 billion and WuXi was acquired by Chinese private equity group for USD 3.3 billion. Patent cliff, high R&D cost, and standardization in clinical trials process have increased the demand for outsourcing companies. LabCorp acquired Covance to gain larger market share. In addition, IT companies providing data management platforms are collaborating with CROs.

Restraint: Presence Of Suitable Alternative

The growing concern of animal welfare organizations regarding the safety and the well-being of animals is expected to impact the in-vivo CRO market. According to them, animals must not be hurt and sacrificed for the development of drugs for human use. In order to satisfy these agencies, an ancillary industry is now being set up, which is working towards the development of alternative methods for drug testing and validation instead of in-vivo analysis performed on animals. A strong resistance has been developed over the past few decades by animal welfare organizations, such as PETA, which are probing the effectiveness and necessity of animal use in preclinical trials.

What Does This Report Include?

This section will provide insights into the contents included in this oncology based in-vivo CRO market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Oncology based in-vivo CRO market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Oncology based in-vivo CRO market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.